"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."

NCT05249881 · Unknown status

Last updated 2026-05-28

This clinical trial tested the effects of a weekly injection called semaglutide in adults with type 2 diabetes to see how it impacts blood sugar levels and weight.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Early Phase 1 First exploratory testing in people.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 300 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2022-03 · est. completion 2022-12

Where 2 sites · Pakistan

What this study is testing ClinicalTrials.gov NCT05249881 ↗

Description as written by the study sponsor.

A prospective interventional trial for 9 months will be carried out on 300 type-2 diabetes mellitus volunteer patients who are above 18-year-old and participants will be selected through consecutive sampling and will be evaluated on the basis of glycemic index and history of patients. Selected parameters will be measured at baseline and after the 12 weeks of therapy. Statistical analysis will be carried out by SPSS, ANOVA, and t-test. From this experimental design, we are expecting improvement in the management of glycemic index, reduction in systolic and diastolic blood pressure, and reduction in weight GLP-1 naive patients.

Treatments tested

Semaglutide Pen Injector also known as Ozempic Drug

All Diabetes mellitus type2 patients fulfilling the inclusion criteria, will receive 0.25mg Semaglutide injection per week and after two weeks dosage will be escalated to 0.5 mg/week for next 10 weeks.

Main thing measured	Change in glycemic Index in Diabetes mellitus type-2 Patients
Sponsor	Aga Khan University
Conditions studied	Diabetes Mellitus, Type 2, Weight Change, Body
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05249881 ↗